Provided by Tiger Fintech (Singapore) Pte. Ltd.

Black Diamond Therapeutics, Inc.

2.31
-0.1200-4.94%
Post-market: 2.310.00000.00%19:49 EDT
Volume:567.77K
Turnover:1.32M
Market Cap:131.35M
PE:26.22
High:2.38
Open:2.34
Low:2.30
Close:2.43
Loading ...

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

GlobeNewswire
·
19 Mar

Black Diamond Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
10 Mar

Black Diamond Therapeutics Reports 2024 Financial Results

TIPRANKS
·
08 Mar

Black Diamond Therapeutics price target lowered to $15 from $16 at Stifel

TIPRANKS
·
07 Mar

Black Diamond Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
07 Mar

Black Diamond Therapeutics Inc : Wedbush Cuts Target Price to $11 From $16

THOMSON REUTERS
·
07 Mar

Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating

MT Newswires Live
·
07 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX) and Passage Bio (PASG)

TIPRANKS
·
07 Mar

Black Diamond: Q4 Earnings Snapshot

Associated Press Finance
·
07 Mar

Black Diamond Therapeutic Q4 EPS $(0.28) Beats $(0.31) Estimate

Benzinga
·
07 Mar

Black Diamond Therapeutics Q4 Cash & Investments USD 98.6 Million

THOMSON REUTERS
·
07 Mar

Black Diamond Therapeutics Q4 Net Income USD -15.985 Million

THOMSON REUTERS
·
07 Mar

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
07 Mar

Naya Biosciences Announces Nomination of New Board Members

THOMSON REUTERS
·
19 Feb

NAYA Biosciences Announces Nomination of New Board Members

GlobeNewswire
·
19 Feb